In life sciences today, time is the biggest barrier between strategic questions and meaningful answers. Whether launching a new therapy, preparing for label expansion, or navigating market access challenges, medical affairs and commercial teams must quickly understand and navigate how stakeholders perceive and respond to data.
As the pharmaceutical supply chain transitions into full compliance with the Drug Supply Chain Security Act (DSCSA), one issue that has been simmering below the surface for years is now starting to boil over: exception handling. While much of the attention has focused on barcodes, serialization data feeds, and SOP enforcement, the day-to-day disruptions caused by data and product mismatches are becoming a defining challenge, especially as dispensers have now moved into full compliance as of November 27, 2025.
